CLLS Cellectis SA ADRs

Cellectis SA is a gene-editing company, employing its core proprietary technologies to develop products in the emerging field of immuno-oncology. Its two segment includes Therapeutics and Plants. This is an ADR of a company whose stock trades outside of the U.S. as the symbol FP:ALCLS.

$6.16  -0.28 (-4.35%)
As of 01/27/2022 15:59:58 EST     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  ADRs
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  France
Country of incorporation:  France
IPO date:  03/25/2015
Outstanding shares:  45,484,310
Average volume:  261,379
Market cap:   $298,831,917
Current dividend yield:  0.00%
All SEC filings:   SEC Edgar Online
Annual filings:      20-F
Sedol:      BWFKZT2
Valuation   (See tab for details)
PE ratio:   -2.28
PB ratio:   1.23
PS ratio:   5.06
Return on equity:   -54.07%
Net income %:   -218.08%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy